Merck Faces Execution Risks as Analysts Press Pipeline Promise
Merck's stock has seen a significant surge of +59% in the past year, reaching near its all-time high. The company's management has outlined a vision for a commercial opportunity exceeding $70 billion from new products that will carry it beyond the patent expiration of KEYTRUDA.
The central concern for investors is the post-KEYTRUDA earnings profile, with some worrying about a revenue cliff. However, Merck's CEO described this period as 'more of a hill than a cliff,' anticipating a 'shallow dip with a fast return back to growth.'
One key test of this promise will be the launch of LIPFENDRA, an oral drug for lowering cholesterol. Analysts have questioned the commercial hurdles in primary care, highlighting the challenges faced by injectable alternatives.
The company has acknowledged that it will 'take time to get access established' and that the initial pace might not be 'as fast out of the gate.' This underscores the immense execution challenge ahead for Merck as it seeks to turn its pipeline promise into a post-KEYTRUDA reality.